Acumen Pharmaceuticals, Inc. (ABOS) Misses Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ABOS Hot Sheet
Join SI Premium – FREE
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q2 EPS of ($0.45), $0.09 worse than the analyst estimate of ($0.36).
For earnings history and earnings-related data on Acumen Pharmaceuticals, Inc. (ABOS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Parametric Sound (PAMT) Misses Q3 EPS by 31c
- Offerpad Solutions Inc. (OPAD) Misses Q3 EPS by 72c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
